Trial Profile
A Pilot Study of the Neo-adjuvant Use of Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Cobimetinib (Primary) ; Vemurafenib (Primary)
- Indications Cancer metastases; Malignant melanoma
- Focus Therapeutic Use
- Sponsors Sunnybrook Health Sciences Centre
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 25 Oct 2022 Planned End Date changed from 1 Oct 2022 to 31 Jan 2024.
- 25 Oct 2022 Planned primary completion date changed from 1 Oct 2022 to 31 Jan 2024.